SCHEMBL22266136

SCHEMBL22266136

O=C(O)N1CC[C@H](Oc2ccc(F)c(F)c2)C1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 2/20 0.47
HRH1 P35367 1/20 0.47
ACACB O00763 3/20 0.46
GRIN1 Q05586 2/20 0.45
GRIN2B Q13224 2/20 0.45
GPR119 Q8TDV5 1/20 0.44
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
CNR1 P21554 1/20 0.43
HRH3 Q9Y5N1 2/20 0.42
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
EGFR P00533 1/20 0.41
LIPG Q9Y5X9 2/20 0.41
LIPC P11150 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
S1PR3 Q99500 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28679420 1.00 CCR3 (0.47) CCR3HRH1ACACBGRIN1GRIN2B
SCHEMBL22265896 1.00 CCR3 (0.47) CCR3HRH1ACACBGRIN1GRIN2B
SCHEMBL5102206 0.92 HRH1 (0.52) CCR3HRH1ACACBGRIN1GRIN2B
SCHEMBL23365192 0.88 GRIN1 (0.48) CCR3HRH1ACACBGRIN1GRIN2B
SCHEMBL28594854 0.87 LIPG (0.45) ACACBGPR119PTGS1PTGS2LIPG
SCHEMBL21825045 0.85 TRPV4 (0.54) ACACBGPR119FFAR4
SCHEMBL22278076 0.82 GPR119 (0.62) GPR119HRH3S1PR3
SCHEMBL22278074 0.82 GPR119 (0.62) GPR119HRH3S1PR3
SCHEMBL22278067 0.82 GPR119 (0.62) GPR119HRH3S1PR3
SCHEMBL21824793 0.82 HRH3 (0.43) ACACBGPR119PTGS1PTGS2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230116101-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. 2023-04-13 US disclosed
CN-113906019-A Compound and use thereof 优曼尼蒂治疗公司 2022-01-07 CN disclosed
EP-3914593-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2021-12-01 EP disclosed
WO-2021097240-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2021-05-20 WO disclosed
US-20210139471-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2021-05-13 US disclosed
WO-2020154571-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230116101-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 CCR3 1928/4885HRH1 4085/4885ACACB 664/4885
US-20210139471-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 CCR3 1928/4885HRH1 4085/4885ACACB 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.